Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Liabilities: 2014-2025

Historic Total Liabilities for Zevra Therapeutics (ZVRA) over the last 10 years, with Sep 2025 value amounting to $137.0 million.

  • Zevra Therapeutics' Total Liabilities rose 12.46% to $137.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.0 million, marking a year-over-year increase of 12.46%. This contributed to the annual value of $138.5 million for FY2024, which is 25.35% up from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Total Liabilities is $137.0 million, which was down 1.51% from $139.0 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Total Liabilities peaked at $139.0 million during Q2 2025, and registered a low of $5.4 million during Q3 2021.
  • For the 3-year period, Zevra Therapeutics' Total Liabilities averaged around $105.8 million, with its median value being $111.9 million (2024).
  • Per our database at Business Quant, Zevra Therapeutics' Total Liabilities tumbled by 92.59% in 2021 and then skyrocketed by 672.01% in 2022.
  • Quarterly analysis of 5 years shows Zevra Therapeutics' Total Liabilities stood at $5.8 million in 2021, then skyrocketed by 590.71% to $40.2 million in 2022, then skyrocketed by 174.65% to $110.5 million in 2023, then increased by 25.35% to $138.5 million in 2024, then climbed by 12.46% to $137.0 million in 2025.
  • Its last three reported values are $137.0 million in Q3 2025, $139.0 million for Q2 2025, and $131.7 million during Q1 2025.